In Addition, Such Combined Use In Patients With Kidney Disease Or Diabetes Increases Risks Of Having A Stroke As Well As Fainting And Falling
In February 2014 Health Canada issued new safety information about the drug Tekturna (aliskiren) as regards its use in combination with some other blood pressure medications.
From "New warnings regarding blood pressure drugs" we get this drug safety guidance:
Recent studies have demonstrated that any combination of [Tekturna (aliskiren)], [angiotensin-converting enzyme (ACE) inhibitor] or [angiotensin receptor blocker (ARB)] increases the risks of hypotension (low blood pressure), hyperkalemia (high levels of potassium in the blood) and kidney problems.
Strictly Confidential, No Obligation.
Furthermore, [Tekturna (aliskiren)] should not be taken in combination with [any ACE] or with [any ARB] in patients with diabetes or kidney disease due to the additional risks of stroke and syncope (fainting) in these patients.
We have written in more detail about the increased risks of serious side effects associated with Tekturna in this 2012 article: "Tekturna And Other Aliskiren Related Blood Pressure Medications Can Cause Renal Failure, Kidney Complications, And Strokes".
As stated at the end of that earlier article, we will continue to monitor the safety issues involving Tekturna, and report significant developments here.